NDAINTRAVENOUSSOLUTION
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE (pantoprazole sodium in 0.9% sodium chloride) by Baxter is (h, k)-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for pathological hypersecretory conditions including zollinger-ellison (ze) syndrome in adults. First approved in 2024.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pantoprazole sodium 0.9% sodium chloride is an intravenous proton pump inhibitor that blocks the (H,K)-ATPase enzyme on gastric parietal cells, inhibiting gastric acid secretion with effects persisting beyond 24 hours. It is indicated for pathological hypersecretory conditions including Zollinger-Ellison Syndrome in adults. The IV formulation provides rapid acid suppression for patients unable to take oral medication.
Growth
Recent 2024 approval signals early-stage commercialization with opportunity for brand building in a specialized indication with moderate competitive pressure.
Mechanism of Action
(H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H, K)-ATPase results in a duration of antisecretory effect that persists longer…
Career Relevance
This newly approved IV pantoprazole product offers entry-level to mid-career professionals the opportunity to build brand presence in a specialty indication with moderate competition. The growth lifecycle and recent approval suggest active commercialization efforts, particularly in hospital and specialty pharmacy channels where IV medications are distributed.
Worked on PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.